Global Camrelizumab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Camrelizumab market size was valued at US$ 695 million in 2025 and is forecast to a readjusted size of US$ 1460 million by 2032 with a CAGR of 6.5% during review period.
Camrelizumab is a humanized anti-PD-1 monoclonal antibody. By specifically binding to the PD-1 receptor on the surface of T cells, it blocks its interaction with the ligands PD-L1 and PD-L2, relieves the suppression of immune cells in the tumor microenvironment, and restores and activates the body’s own anti-tumor immune response, thereby exerting a tumor-killing effect. As an immune checkpoint inhibitor independently developed by Hengrui Medicine, this drug features high affinity, long-lasting efficacy and controllable safety. Its approved indications widely cover liver cancer, lung cancer, esophageal cancer, nasopharyngeal cancer, cervical cancer and other tumors. It is often used in combination with chemotherapy and targeted drugs such as famitinib malate, significantly improving survival benefits for patients with advanced malignant tumors, making it one of the most widely used immunotherapeutic drugs in clinical practice in China.In 2025, global Camrelizumab production reached approximately 18.9 million units.
Camrelizumab, a humanized anti-PD-1 monoclonal antibody independently developed by Hengrui Medicine, is one of the core products in the domestic immunotherapy market. With extensive indication coverage, mature combination therapy regimens, medical insurance coverage and channel expansion to primary markets, it occupies an important position in the domestic PD-1 market. Its approved indications cover multiple high-incidence tumors including lung cancer, liver cancer, esophageal cancer, nasopharyngeal cancer and cervical cancer, making it one of the PD-1 products with the most abundant approved indications in China. In the competitive landscape, camrelizumab forms the first echelon alongside domestic PD-1 inhibitors from companies such as Innovent Biologics, BeiGene and Junshi Biosciences, consolidating its market share through advantages in medical insurance pricing, penetration in grassroots medical markets and superior data from combination therapies. With continuous volume growth driven by medical insurance, expansion of new indications and advancement in overseas markets, its market influence has been steadily rising, establishing it as a benchmark product in the field of tumor immunotherapy in China.
This report is a detailed and comprehensive analysis for global Camrelizumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Camrelizumab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Camrelizumab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Camrelizumab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Camrelizumab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Camrelizumab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Camrelizumab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Suzhou Sundia Bio-Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Camrelizumab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
200mg / Vial
100mg / Vial
Market segment by Antibody Type
Monoclonal Antibody
Polyclonal Antibody
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Lung Cancer
Liver Cancer
Esophageal Cancer
Others
Major players covered
Suzhou Sundia Bio-Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Camrelizumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Camrelizumab, with price, sales quantity, revenue, and global market share of Camrelizumab from 2021 to 2026.
Chapter 3, the Camrelizumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Camrelizumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Camrelizumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Camrelizumab.
Chapter 14 and 15, to describe Camrelizumab sales channel, distributors, customers, research findings and conclusion.